Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs

Acta Psychiatrica Scandinavica

Volumn 110, Issue 4, 2004, Pages 299-305

  Paton, C ^a   Esop, R ^a   Young, C ^b   Taylor, D ^b  

^a OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antipsychotics; Dyslipidaemia; Obesity; Schizophrenia; Smoking

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; HEALTH SURVEY; HIP; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MORBIDITY; MORTALITY; OBESITY; POLYPHARMACY; POPULATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK FACTOR; SCHIZOPHRENIA; SCREENING TEST; SMOKING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; SMOKING; TRIGLYCERIDES;

EID: 4644304204     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2004.00372.x     Document Type: Article

References (45)

1. NEWMAN SC, BLAND RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-245.
2. BROWN S. Excess mortality of schizophrenia. Br J Psychiatry 1997;171:502-508.
3. BROWN S, INSKIP H, BARRACLOUGH B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-217.
4. BLACK DW, WARACK G, WINOKUR G. The excess mortality among psychiatric patients: the Iowa record-linkage study. JAMA 1985;253:58-61.
5. BROOK OH. Mortality in the long-stay population of Dutch mental hospitals. Acta Psychiatr Scand 1985;71:626-635.
6. ALLEBECK P, VARLA A, WISTEDT B. Mortality in schizophrenia: a 10-year follow up based on the Stockholm county inpatient register. Arch Gen Psych 1998;43:650-653.
7. MORTENSEN PB, JUEL K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993;163:183-189.
8. BROWN S, BIRTWISTLE J, ROE L, THOMPSON C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701.
9. MASTERSON E, O'SHEA B. Smoking and malignancy in schizophrenia. Br J Psychiatry 1984;145:429-432.
10. GREEN AL, SALOMON MS, BRENNER MJ, RAWLINS K. Treatment of schizophrenia and comorbid substance use disorder. Current Drug Targets CNS Neurol Disord 2002;1:129-139.
11. VALSAMAKIS G, CHETTY RK, KUMAR S. The management of obesity in type II diabetes mellitus. Cur Med Res Opin 2002;18(Suppl. 1):75-81.
12. National Audit Office. Tackling obesity in England. London: HMSO, 2001.
13. MEYER JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62(Suppl. 27):27-34.
14. ALLISON DB, FONTAINE KR, HEO M et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220.
15. THAKORE J, VLAHOOS J, MARTINE A, REZNEK R. Increased visceral fat distribution in drug naïve and drug free patients with schizophrenia. Int J Obesity 2002;26:137-141.
16. BJORNTORP P. The association between obesity, adipose tissue distribution and disease. Acta Med Scand 1987;723:121-134.
17. RYAN MCM, THAKORE JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71:239-257.
18. SERNYAK MJ, DOUGLAS L, ALARCON RD, LOSONCZY MF, ROSENHECK R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566.
19. MELKERSSON KI, HUNTING AL, BRISMAR KE. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-749.
20. GAULIN BD, MARKOWITZ JS, CALEY CF, NESBITT LLA, DUFRESNE RL. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;158:1270-1272.
21. HENDERSON DC, CAGLIERO E, GRAY C, NASRALLAH RA, HAYDEN DL, SCHOEFELD DA. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a 5-year naturalistic study. Am J Psychiatry 2000;57:975-981.
22. OSSER DN, NAJARIAN DM, DUFRESNE RL. Olanzapine increases in weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770.
23. DURRINGTON P. Dyslipidaemia. Lancet 2003;362:717-731.
24. BENOWITZ NL, HANNSON A, JACOB P. Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 2002;39:1107-1112.
25. British Cardiac Society. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl. 2):1-29.
26. Department of Health. National service framework for coronary heart disease, Chapter 2, 2003. http://www.doh.uk/nsf/coronarych2.htm.
27. British Heart Foundation. Any questions? 2003. http://www.bhf.org.uk.
28. PRIMATESTA P, HIRANI V. Health survey for England - the health of minority ethnic groups, 1999. http://www.official-documents.co.uk.
29. LARSSON B, SVARDSUDD K, WELIN L, WILHELMSEN L, BJORNTORP P, TIBBIN G. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death; 13-year follow-up of participants in the study of men born in 1913. BMJ 1984;288:1401-1404.
30. LAPIDUS L, BENGTSSON C, LARSSON B, PENNERT K, RYBO E, SJOSTROM L. Distribution of adipose tissue and risk of cardiovascular disease and death; 12-year follow up of participants in the population study of women in Gotenburg, Sweden. BMJ 1984;289:1257-1261.
31. ALLISON DB, JANET L, MENTORE MS, MOONSEONG H, CHANDLER L, CAPPELLERI JC et al. Antipsychotic induced weight gain; a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1695.
32. TAYLOR DM, MCASKILL R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-432.
33. O'KEEFE CD, NOORDSY DL, LISS TB, WEISS H. Reversal of antipsychotic-associated weight gain. J Clin Psychiatry 2003;64:907-912.
34. BROWN S. About obesity. International task force report, 2003. http://www.obesite.chaire.ulaual.ca/iotf.htm.
35. British Broadcasting Corporation. NHS failing to tackle obesity, 2003. http://www.druginfozone.nhs.uk/Record%20Viewing/vR.aspx?id=522524.
36. Reductil Summary of Product Characteristics 2003. http://emc.vhn.net.
37. WERNEKE J, TAYLOR D, SANDERS T, WESSELY S. Behavioural management of antipsychotic induced weight gain: a review. Acta Psychiatr Scand 2003;108:252-259.
38. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo controlled trial. Lancet 2002;360:7-22.
39. SPRING B, PINGITORE R, MCECHARGUE DE. Reward value of cigarette smoking for comparably heavy smoking schizophrenic, depressed and non-patient smokers. Am J Psychiatry 2003;160:316-322.
40. GOFF DC, HENDERSON DC, AMICO E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992;149:1189-1194.
41. JORENBY DE, LEISCHOW SJ, NIDES MA, RENNARD SI, JOHNSTON JA, HUGHES AR. A controlled trial of sustained release bupropion, a nicotine patch or both for smoking cessation. N Eng J Med 1999;340:685-691.
42. JAMERSON BFD, NIDES M, JORENBY DE, DONAHUE R, GARRETT P, JOHNSTON JA. Late term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy and placebo. Clin Therap 2001;23:744-752.
43. PARROTT AC. Cigarette-derived nicotine is not a medicine. World J Biol Psychiatry 2003;4:49-55.
44. VAN DONGEN CJ, KRIZ P, FOX KA, HAQUE I. A quit smoking group: a pilot study. J Psychosoc Nurs Ment Health Serv 1999;37:31-37.
45. ADDINGTON J, EL-GUEBALY N, CAMBELL W, HODGINS DC, ADDINGTON D. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 1998;155:974-976.